15 Dividend Zombies to Invest in

4. Eli Lilly and Company (NYSE:LLY)

Consecutive Years of Dividend Payments: 139

An American multinational pharmaceutical company, Eli Lilly and Company (NYSE:LLY) offers a wide range of related products and services to its consumers. The company has experienced rapid growth in recent years, largely driven by the strong performance of its glucagon-like peptide-1 (GLP-1) receptor agonist drugs. The stock has delivered a return of over 7% since the start of 2025.

In the fourth quarter of 2024, Eli Lilly and Company (NYSE:LLY)’s revenue surged 45% to $13.53 billion, fueled by high demand for Mounjaro and Zepbound. Earnings per share (EPS) more than doubled, rising 102% to $4.88. Additionally, the company continued expanding its drug pipeline, securing US approval for Zepbound as a treatment for moderate-to-severe obstructive sleep apnea in adults with obesity, along with approval for Omvoh for managing moderately to severely active Crohn’s disease.

Eli Lilly and Company (NYSE:LLY), one of the best dividend zombies, has been paying dividends to shareholders for 139 years and has raised its payouts for 11 years straight. Currently, its quarterly dividend amounts to $1.50 per share for a dividend yield of 0.72%, as of March 23.

Eli Lilly and Company (NYSE:LLY) was a part of 115 hedge fund portfolios at the end of Q4 2024, growing from 106 in the previous quarter, as per Insider Monkey’s database. The stakes owned by these hedge funds are worth more than $16.6 billion. With over 5.2 million shares, Fisher Asset Management was the company’s leading stakeholder in Q4.